Mudanjiang

Researchers are evaluating the effect of dexmedetomidine on heart muscle damage in patients who have experienced an anterior ST-segment elevation myocardial infarction (STEMI) and are treated with primary percutaneous coronary intervention (pPCI). This double-blind, multicenter, randomized, placebo-controlled trial aims to study whether dexmedetomidine can reduce the size of the heart attack injury compared to placebo. The study plans to enroll 250 patients, aged 18 to 75, admitted within 6 hours of symptom onset. Participants are randomly assigned to receive either intravenous dexmedetomidine or a saline placebo immediately after enrollment and throughout the PCI procedure. The dexmedetomidine dose starts at the maximum maintenance dose allowed (0.7 mcg/kg/h) and can be adjusted within a range of 0.2 to 0.7 mcg/kg/h based on the patient's heart rate, blood pressure, and sedation score. The placebo group receives saline using the same administration method and adjustments. During the study, patients undergo cardiac magnetic resonance imaging (CMR) 5b12 days after STEMI to measure myocardial infarction size, which is the primary outcome. Researchers monitor patients closely during the PCI and assess heart function and safety parameters. The total participation duration and follow-up are planned considering the imaging timeline and clinical monitoring needs.

Researchers are evaluating the efficacy and safety of Yangxinshi tablets in patients with coronary heart disease complicated by cardiac dysfunction. This Phase 4 randomized controlled trial aims to determine whether adding Yangxinshi tablets to conventional treatment can reduce ischemic or heart failure-related clinical events, improve exercise tolerance, and enhance quality of life and mental health in these patients. The study includes 2708 patients aged 40 to 80 years with specific heart conditions and symptoms. Participants are randomly divided into two groups: one group receives conventional treatment plus Yangxinshi tablets (3 tablets, three times daily), while the control group receives only conventional treatment without additional tablets. Conventional treatment includes drugs such as aspirin, beta-blockers, statins, and others aimed at improving outcomes and relieving symptoms. The treatment continues until the expected number of endpoint events occurs or the study ends. During the study, participants are monitored for ischemic events or heart failure-related clinical events, including death, stroke, myocardial infarction, and hospital readmissions. The average follow-up period is about three years. Researchers assess exercise tolerance, quality of life, and mental health, while monitoring safety and overall health status throughout the study.

Researchers are studying the effects of normobaric oxygen (NBO) therapy on patients who have experienced an acute ischemic stroke (AIS) and are transferred for endovascular thrombectomy (EVT). The goal is to assess the safety and effectiveness of NBO in improving functional outcomes three months after stroke. Stroke is a major cause of death and disability worldwide, and while treatments like mechanical thrombectomy can improve blood flow, less than half of patients with large vessel occlusion achieve good recovery. NBO offers potential brain protection by improving oxygen delivery to affected areas and reducing damage through multiple mechanisms. Participants will receive either inhaled 100% oxygen (NBO) or best medical care without NBO. The study focuses on patients transferred for EVT who meet specific stroke severity and imaging criteria. NBO treatment is delivered through oxygen inhalation, aiming to increase oxygen availability to the brain before reperfusion. The study is conducted in a Phase 3 setting and compares outcomes between those receiving NBO and those receiving standard care. During the study, participants will be monitored for disability levels using the modified Rankin scale at 90 days and one year after treatment. Assessments include neurological exams and imaging to confirm stroke details and severity. Researchers will also track safety and functional outcomes to evaluate the impact of NBO therapy. Participants are followed for at least three months after randomization to observe recovery and potential benefits.

Researchers are investigating the effectiveness of drug-coated balloon (DCB) treatment on non-flow limited vulnerable plaques in patients with acute coronary syndrome. This multicenter, prospective, open-label, controlled, randomized trial aims to compare DCB treatment with guideline-directed medical therapy (GDMT) to see if DCB can improve clinical cardiovascular outcomes. The study focuses on patients presenting with acute myocardial infarction or unstable angina who undergo successful stent implantation on culprit lesions. Participants will be divided into two groups: one group will receive DCB treatment on non-culprit lesions after pretreatment, with the option of bail-out stent placement if pretreatment fails. The other group will receive guideline-directed medical treatment alone. The study targets lesions with specific characteristics, such as a diameter between 2.0 and 4.0 mm and length up to 50 mm, meeting detailed imaging criteria. All participants receive standard medical care throughout the trial. During the study, researchers will monitor participants for target lesion failure over 24 months to assess the success of the treatments. Participants must provide informed consent before any procedures. The study will include various assessments such as imaging tests and clinical evaluations to track cardiovascular outcomes. Safety and adherence to treatment protocols will be monitored throughout, with follow-up visits scheduled to evaluate the long-term effects of the interventions.

Researchers are evaluating the safety and effectiveness of TQB2930, a HER2 bispecific antibody drug, combined with a choice of chemotherapy drugs, compared to trastuzumab combined with chemotherapy in people with HER2-positive advanced breast cancer. The study focuses on participants who have already received at least two prior anti-HER2 treatments for their advanced cancer. This is a Phase III clinical trial designed to compare these two treatment approaches. Participants will receive either TQB2930 plus chemotherapy or trastuzumab plus chemotherapy. The chemotherapy options include capecitabine tablets, gemcitabine hydrochloride injection, vinorelbine tartrate injection, and eribulin mesylate injection. Treatments are given according to the investigator's choice alongside the study drugs. The study is randomized, open-label, and conducted at multiple centers. During the study, participants will be monitored for progression-free survival, which means the length of time they live without the cancer worsening, up to about one year. Researchers will assess treatment response through measurable lesions and monitor safety and side effects. Various tests and evaluations will be performed throughout the study to track health status and treatment effects. The study includes follow-up to evaluate the overall outcome and safety of the treatments.